Experience with perioperative pirfenidone for lung cancer surgery in patients with idiopathic pulmonary fibrosis

@article{Iwata2014ExperienceWP,
  title={Experience with perioperative pirfenidone for lung cancer surgery in patients with idiopathic pulmonary fibrosis},
  author={Takeyuki Iwata and Shigetoshi Yoshida and Kaoru Nagato and Takahiro Nakajima and Hidemi Suzuki and Toyoaki Tagawa and Teruaki Mizobuchi and Satoshi Ota and Yukio Nakatani and Ichiro Yoshino},
  journal={Surgery Today},
  year={2014},
  volume={45},
  pages={1263-1270}
}
PurposeIdiopathic pulmonary fibrosis (IPF) is a progressive diffuse lung disease associated with an increased risk of lung cancer. Patients with IPF sometimes develop a life-threatening acute exacerbation of IPF (AE-IPF) after lung cancer surgery. In this retrospective study, pirfenidone, an antifibrotic agent, was perioperatively administered to IPF patients with lung cancer with the aim of preventing postoperative AE-IPF, and the feasibility and clinical outcomes were investigated… CONTINUE READING
BETA

Similar Papers

Figures, Tables, and Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 19 CITATIONS

Effect of Perioperative Pirfenidone Treatment in Lung Cancer Patients With Idiopathic Pulmonary Fibrosis.

  • The Annals of thoracic surgery
  • 2016
VIEW 3 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

Acute exacerbations of progressive-fibrosing interstitial lung diseases.

  • European respiratory review : an official journal of the European Respiratory Society
  • 2018

Lung cancer in patients with idiopathic pulmonary fibrosis.

  • Pulmonary pharmacology & therapeutics
  • 2017
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 36 REFERENCES

Histological characteristics in the prediction of acute exacerbation

O Matsubara, T Ohba, H Ninomiya, Y Ishikawa, E. Mark
  • Surg Today
  • 2015
VIEW 1 EXCERPT